Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig-to-Rhesus Monkey Renal Xenografts.

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-07-01 DOI:10.1111/xen.12880

Andrew B Adams, David Faber, Brendan P Lovasik, Abraham J Matar, Steven C Kim, Christopher Burlak, Matt Tector, Alfred J Tector

{"title":"Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig-to-Rhesus Monkey Renal Xenografts.","authors":"Andrew B Adams, David Faber, Brendan P Lovasik, Abraham J Matar, Steven C Kim, Christopher Burlak, Matt Tector, Alfred J Tector","doi":"10.1111/xen.12880","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the clinically relevant anti-CD40 antibody iscalimab for baseline immunosuppression in a preclinical pig-to-rhesus renal xenograft model.Summary background data: CD40/CD40L co-stimulation blockade-based immunosuppression has been more successful than calcineurin-based protocols in prolonging xenograft survival in preclinical models.Methods: GGTA1 knockout/CD55 transgenic pig kidneys were transplanted into rhesus monkeys (n = 6) receiving an iscalimab-based immunosuppressive regimen.Results: Two grafts were lost early (22 and 26 days) because of ectatic donor ureters with otherwise normal histology. The other recipients survived 171, 315, 422, and 439 days with good renal function throughout the posttransplant course. None of the recipients experienced serious infectious morbidity.Conclusions: It may be reasonable to evaluate an iscalimab-based immunosuppressive regimen in clinical renal xenotransplantation.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/xen.12880","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the clinically relevant anti-CD40 antibody iscalimab for baseline immunosuppression in a preclinical pig-to-rhesus renal xenograft model.

Summary background data: CD40/CD40L co-stimulation blockade-based immunosuppression has been more successful than calcineurin-based protocols in prolonging xenograft survival in preclinical models.

Methods: GGTA1 knockout/CD55 transgenic pig kidneys were transplanted into rhesus monkeys (n = 6) receiving an iscalimab-based immunosuppressive regimen.

Results: Two grafts were lost early (22 and 26 days) because of ectatic donor ureters with otherwise normal histology. The other recipients survived 171, 315, 422, and 439 days with good renal function throughout the posttransplant course. None of the recipients experienced serious infectious morbidity.

Conclusions: It may be reasonable to evaluate an iscalimab-based immunosuppressive regimen in clinical renal xenotransplantation.

查看原文本刊更多论文

伊卡利单抗联合瞬时泰舒单抗可延长猪-恒河猴肾脏异种移植的存活期

目的评估与临床相关的抗CD40抗体伊卡利单抗（iscalimab）在临床前猪-恒河猴肾脏异种移植模型中的基线免疫抑制作用：基于CD40/CD40L共刺激阻断剂的免疫抑制在临床前模型中延长异种移植物存活率方面比基于钙调素的方案更成功：方法：将GGTA1基因敲除/CD55转基因猪肾移植给恒河猴（n = 6），恒河猴接受基于伊卡利单抗的免疫抑制方案：结果：由于供体输尿管异位且组织学正常，两例移植物早期（22 天和 26 天）丢失。其他受者分别存活了171天、315天、422天和439天，移植后肾功能良好。没有一名受者出现严重的感染性疾病：结论：在临床肾脏异种移植中评估基于伊卡利单抗的免疫抑制方案可能是合理的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567